# SV Biotech Crossover Opportunities Fund LP — Form D

SV Biotech Crossover Opportunities Fund LP of LONDON, X0, a pooled investment fund, filed a Form D exempt-offering notice with the SEC on 2022-01-18. The offering totals $350.0M, of which $135.2M was reported sold. Industry: Pooled Investment Fund.

## Offering

- Filed: 2022-01-18
- Form: D
- Accession: 0001903934-22-000001
- Industry: Pooled Investment Fund
- Exemptions: 06b, 3C, 3C.7
- Total offering: $350.0M
- Amount sold: $135.2M
- Remaining: $214.8M
- Investors: 7
- Date of first sale: 2021-12-31
- Security types: equity, fund interests
- Revenue range: Decline to Disclose
- SEC file number: 021-429725

## Issuer

- Name: SV Biotech Crossover Opportunities Fund LP
- CIK: 0001903934
- Entity type: Limited Partnership
- Jurisdiction: UNITED KINGDOM
- Incorporated: 2021
- Address: 71 KINGSWAY, LONDON, X0, WC2B 6ST
- Phone: 44 20 7421 7081

## Officers, directors & promoters (6)

| Name | Role | Location |
| --- | --- | --- |
| N/A SV BCO I GP LLP | Director | London, X0 |
| Houman Ashrafian | Executive Officer | London, X0 |
| Kate Bingham | Executive Officer | London, X0 |
| N/A SV BCO I GP LLP | Executive Officer | London, X0 |
| Nicola Trbovic | Executive Officer | London, X0 |
| N/A SV Health Managers LLP | Promoter | London, X0 |

## More

- [CIK 1903934 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1903934&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001903934-22-000001.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.